Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M. Linch DC, et al. Among authors: holte h. Br J Haematol. 2010 Apr;149(2):237-43. doi: 10.1111/j.1365-2141.2010.08081.x. Epub 2010 Mar 1. Br J Haematol. 2010. PMID: 20201949 Free article. Clinical Trial.
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH. Sweetenham JW, et al. Among authors: holte h. J Clin Oncol. 2001 Jun 1;19(11):2927-36. doi: 10.1200/JCO.2001.19.11.2927. J Clin Oncol. 2001. PMID: 11387366 Clinical Trial.
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G. Blystad AK, et al. Among authors: holte h. Br J Haematol. 2004 Jun;125(5):605-12. doi: 10.1111/j.1365-2141.2004.04951.x. Br J Haematol. 2004. PMID: 15147376 Free article.
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. van Oers MH, et al. Among authors: holte h. Blood. 2006 Nov 15;108(10):3295-301. doi: 10.1182/blood-2006-05-021113. Epub 2006 Jul 27. Blood. 2006. PMID: 16873669 Free article. Clinical Trial.
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H. Eide MB, et al. Among authors: holte h. Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Br J Haematol. 2011. PMID: 21241276 Free article. Review.
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.
Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B. Bosly A, et al. Among authors: holte h. Oncologist. 2013;18(11):1189. doi: 10.1634/theoncologist.2013-0223. Epub 2013 Oct 8. Oncologist. 2013. PMID: 24105750 Free PMC article. Clinical Trial.
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H. Smeland KB, et al. Among authors: holte h. Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23. Br J Haematol. 2016. PMID: 26914167 Free article.
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H. Coiffier B, et al. Among authors: holte h. Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24. Br J Haematol. 2016. PMID: 27010483 Free article. Clinical Trial.
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A. Holte H, et al. Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6. Br J Haematol. 2018. PMID: 30080252 Free PMC article. Clinical Trial.
287 results